Motivation For Starvation: Understanding The Neurobiology Of Anorexia Nervosa
Funder
National Health and Medical Research Council
Funding Amount
$773,142.00
Summary
Anorexia nervosa is a debilitating psychiatric disorder which is currently untreatable. It is characterised by disrupted reward and cognitive processing. This project, which will ultimately inform treatment strategies, utilises the activity-based anorexia rat model combined with innovative behavioural paradigms and sophisticated techniques to manipulate and record from neural circuits. This will furnish a comprehensive understanding of the neurobiology involved in pathological weight loss.
Antibiotic Potentiators As An Alternative Therapeutic Option For The Treatment Of Extensively Drug-resistant Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$856,858.00
Summary
Antibiotic mono-therapies are increasingly ineffective for hard-to-treat bacterial infections, forcing clinicians to rely on combinations of antibiotics. Our project has identified compounds that have weak to no antimicrobial potency in their own right, yet when combined with an existing antibiotic they potentiate its activity and restore its ability to treat resistant infections. These antibiotic potentiators are exciting alternatives to current therapies with reduced risk of induced resistance
Uncovering Oxytocin And Vasopressin Release And Functions With Novel Optical Tools
Funder
National Health and Medical Research Council
Funding Amount
$631,634.00
Summary
Oytocin and vasopressin are peptides in the brain that act as releasable neuromodulators and the balance of these peptides is implicated in the control of social behaviour and anxiety. We aim to investigate the release and function of these neuropeptides with 3 novel protein-based tools in a stressful learning paradigm and anxious behaviour. The understanding of their function will have important implications in the development of therapeutics for neurological conditions and drug addictions.
Examining The Metabolic And Cognitive Deficits Caused By Insulin Resistance In The Ventral Striatum
Funder
National Health and Medical Research Council
Funding Amount
$400,372.00
Summary
Brain insulin resistance is thought to cause metabolic and cognitive deficits, but the underlying neural mechanisms remain elusive. This project addresses this gap in our knowledge by examining how brain insulin resistance disrupts the metabolic regulation of food intake and the cognitive control of actions. The outcomes will provide new insights in disorders characterised by brain insulin resistance such as obesity and dementia.
Neonatal Therapy For Improving Myelination And Long Term Outcome Following Preterm Birth
Funder
National Health and Medical Research Council
Funding Amount
$799,883.00
Summary
Preterm birth leads to the early loss of the nurturing uterine environment which supports key developmental processes. This results in behavioural disorders later in life including attention deficit hyperactivity disorder and anxiety. Preterm birth leads to loss of support for the maturation of oligodendrocyte cells and myelination which contributes to these disorders. This work will delineate therapies for preterm neonates that restore myelination and improve long-term behavioural outcomes.
Improving Clinical Outcomes Of Antimicrobial Resistant Infections With A Drug-free Intervention
Funder
National Health and Medical Research Council
Funding Amount
$999,581.00
Summary
Superbugs, or antimicrobial-resistant pathogens, cause recurring infections and non-healing wounds after surgery as existing therapies fail to effectively kill them. We will develop a medical device to fight superbugs with UV light that is effective against bacteria and fungi without causing harm to human cells. This could eradicate superbugs at infection sites, aid wound healing and actively improve health outcomes after surgery.
Hijacking A Death Switch In Pancreatic And Lung Cancer Cells To Develop A Novel Therapy
Funder
National Health and Medical Research Council
Funding Amount
$738,947.00
Summary
Pancreatic (PC) and lung (LC) cancer have a high mortality rate and poor response to current treatments. We have identified a protein whose inhibition in both PC and LC cells sensitises them to a cancer-cell specific therapy called TRAIL and switches signals that normally promote tumour growth into tumour death signals. This project aims to develop a novel therapeutic that inhibits our target and delivers TRAIL to PC and LC tumours, and could potentially improve survival for PC and LC patients.
Therapeutic Induction Of Tertiary Lymph Nodes In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$995,010.00
Summary
Immunotherapy has been an important recent advance in cancer treatment by using the body's own immune cells to fight cancer. Although there have been unprecedented dramatic results, not all patients benefit, and most benefits are temporary. The cellular environment in which cancers are embedded is crucial for controlling treatment success. We aim to apply novel 'precision' therapies to this environment to expose the cancer and enable attack by immune cells for improved immunotherapy.
Developing Smart Nanomedicine To Enable Advanced Diagnosis And Stimuli-responsive Treatment For Atherosclerosis And Thrombosis
Funder
National Health and Medical Research Council
Funding Amount
$523,342.00
Summary
The early detection and accurate characterization of life-threatening diseases such as cardiovascular diseases are critical to the design of treatment. A therapeutic approach that provides an efficient treatment with minimal side-effects is highly desired by both patients and healthcare systems. This project aims to develop smart nanomedicine with incorporated diagnostic sensor and external stimuli-responsive treatment mechanisms for cardiovascular diseases.
New Therapies Requiring Ultra Large Scale Monoclonal Ab Production In Microalgae
Funder
National Health and Medical Research Council
Funding Amount
$630,089.00
Summary
Monoclonal antibodies target pathogens and molecules with exquisite specificity, and are essential for therapeutics and diagnostics. They are currently made using high-tech/limited-capacity mammalian cell cultures which limit them to low-dose applications. We aim to enable new, high-dose antibody therapies (e.g. antiviral treatments, passive immunisation) via rapid, low-cost, dramatically larger-scale production of valuable medicinal antibodies in a photosynthetic-driven, green algae system.